Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 4-(3-methylbutoxy)-benzenamine, monohydrochloride
- Correlated keywords
- .DELTA.5/.DELTA.6-desaturases inhibitors inhibits DELTA5/DELTA6-desaturases D5/D6-desaturases fatty acids hydrochlorides CP-24879
- Product Overview:
Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of ?5/?6 desaturase.{10907} Mice injected with CP 24,879 at 3 mg/kg had a reduction of liver arachidonate content of approximately 50%. Murine mastocytoma cells treated with 5 µM CP 24,879 showed increased mead acid content and nearly complete ablation of leukotriene C4 synthesis, consistent with a desaturase inhibition-induced state of essential fatty acid deficiency.{10906}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.